O	0	10	Comparison
O	11	13	of
O	14	17	the
B-intervention	18	26	sentinel
I-intervention	27	31	node
I-intervention	32	41	procedure
O	42	49	between
B-eligibility	50	58	patients
I-eligibility	59	63	with
I-eligibility	64	74	multifocal
I-eligibility	75	78	and
I-eligibility	79	87	unifocal
I-eligibility	88	94	breast
I-eligibility	95	101	cancer
O	102	104	in
O	105	108	the
O	109	114	EORTC
O	115	120	10981
O	120	121	-
O	121	126	22023
O	127	133	AMAROS
O	134	139	Trial
O	139	140	:
O	141	155	identification
O	156	160	rate
O	161	164	and
O	165	170	nodal
O	171	178	outcome
O	178	179	.

O	180	190	Multifocal
O	191	197	breast
O	198	204	cancer
O	205	207	is
O	208	218	associated
O	219	223	with
O	224	225	a
O	226	232	higher
O	233	237	risk
O	238	240	of
O	241	246	nodal
O	247	258	involvement
O	259	267	compared
O	268	270	to
O	271	279	unifocal
O	280	286	breast
O	287	293	cancer
O	294	297	and
O	298	301	the
O	302	310	drainage
O	311	318	pattern
O	319	323	from
O	324	334	multifocal
O	335	348	localisations
O	349	352	may
O	353	355	be
O	356	365	different
O	365	366	.

O	367	370	For
O	371	375	this
O	376	382	reason
O	382	383	,
O	384	387	the
O	388	393	value
O	394	396	of
O	397	400	the
O	401	409	sentinel
O	410	414	node
O	415	421	biopsy
O	422	423	(
O	423	426	SNB
O	426	427	)
O	428	437	procedure
O	438	441	for
O	442	446	this
O	447	457	indication
O	458	460	is
O	461	468	debated
O	468	469	.

O	470	473	The
O	474	477	aim
O	478	480	of
O	481	484	the
O	485	492	current
O	493	501	analysis
O	502	505	was
O	506	508	to
O	509	517	evaluate
O	518	521	the
O	522	530	sentinel
O	531	535	node
O	536	550	identification
O	551	555	rate
O	556	559	and
O	560	565	nodal
O	566	577	involvement
O	578	580	in
O	581	589	patients
O	590	594	with
O	595	596	a
O	597	607	multifocal
O	608	614	tumour
O	615	617	in
O	618	621	the
O	622	627	EORTC
O	628	633	10981
O	633	634	-
O	634	639	22023
O	640	646	AMAROS
O	647	652	trial
O	652	653	.

O	654	658	From
O	659	662	the
O	663	668	first
B-total-participants	669	673	4000
O	674	684	registered
O	685	693	patients
O	693	694	,
B-intervention-participants	695	698	342
O	699	703	were
O	704	714	identified
O	715	719	with
O	720	721	a
O	722	732	multifocal
O	733	739	tumour
O	740	742	on
O	743	755	histological
O	756	767	examination
O	768	771	and
O	772	780	compared
O	781	783	to
O	784	785	a
O	786	794	randomly
O	795	803	selected
B-control	804	811	control
I-control	812	817	group
O	818	820	of
B-control-participants	821	824	684
O	825	833	patients
O	834	838	with
O	839	840	a
O	841	849	unifocal
O	850	856	tumour
O	856	857	.

O	858	861	The
O	862	869	outcome
O	870	872	of
O	873	876	the
O	877	880	SNB
O	881	884	was
O	885	893	assessed
O	893	894	.

O	895	898	The
B-outcome	899	907	sentinel
I-outcome	908	912	node
O	913	916	was
O	917	927	identified
O	928	930	in
B-iv-bin-percent	931	933	96
I-iv-bin-percent	933	934	%
O	935	937	of
O	938	941	the
O	942	950	patients
O	951	955	with
O	956	957	a
O	958	968	multifocal
O	969	975	tumour
O	976	979	and
O	980	982	in
B-cv-bin-percent	983	985	98
I-cv-bin-percent	985	986	%
O	987	989	of
O	990	995	those
O	996	1000	with
O	1001	1009	unifocal
O	1010	1017	disease
O	1017	1018	.

O	1019	1021	In
O	1022	1025	the
O	1026	1036	multifocal
O	1037	1042	group
O	1042	1043	,
B-iv-bin-percent	1044	1046	51
I-iv-bin-percent	1046	1047	%
O	1048	1051	had
O	1052	1053	a
B-outcome	1054	1064	metastasis
O	1065	1067	in
O	1068	1071	the
O	1072	1080	sentinel
O	1081	1085	node
O	1086	1094	compared
O	1095	1097	to
B-cv-bin-percent	1098	1100	28
I-cv-bin-percent	1100	1101	%
O	1102	1104	in
O	1105	1108	the
O	1109	1117	unifocal
O	1118	1123	group
O	1123	1124	;
O	1125	1128	and
O	1129	1136	further
B-outcome	1137	1142	nodal
I-outcome	1143	1154	involvement
I-outcome	1155	1160	after
I-outcome	1161	1162	a
I-outcome	1163	1171	positive
I-outcome	1172	1180	sentinel
I-outcome	1181	1185	node
O	1186	1189	was
O	1190	1195	found
O	1196	1198	in
B-iv-bin-percent	1199	1201	40
I-iv-bin-percent	1201	1202	%
O	1203	1204	(
B-iv-bin-abs	1204	1206	38
O	1206	1207	/
B-intervention-participants	1207	1209	95
O	1209	1210	)
O	1211	1214	and
B-cv-bin-percent	1215	1217	39
I-cv-bin-percent	1217	1218	%
O	1219	1220	(
B-cv-bin-abs	1220	1222	39
O	1222	1223	/
B-control-participants	1223	1226	101
O	1226	1227	)
O	1228	1240	respectively
O	1240	1241	.

O	1242	1244	In
O	1245	1249	this
O	1250	1261	prospective
O	1262	1275	international
O	1276	1287	multicentre
O	1288	1293	study
O	1293	1294	,
O	1295	1298	the
O	1299	1301	96
O	1301	1302	%
O	1303	1312	detection
O	1313	1317	rate
O	1318	1327	indicates
O	1328	1332	that
O	1333	1336	the
O	1337	1340	SNB
O	1341	1350	procedure
O	1351	1354	can
O	1355	1357	be
O	1358	1364	highly
O	1365	1374	effective
O	1375	1377	in
O	1378	1386	patients
O	1387	1391	with
O	1392	1393	a
O	1394	1404	multifocal
O	1405	1411	tumour
O	1411	1412	.

O	1413	1419	Though
O	1420	1423	the
O	1424	1430	tumour
O	1430	1431	-
O	1431	1439	positive
O	1440	1444	rate
O	1445	1447	of
O	1448	1451	the
O	1452	1460	sentinel
O	1461	1465	node
O	1466	1469	was
O	1470	1475	twice
O	1476	1478	as
O	1479	1483	high
O	1484	1486	in
O	1487	1490	the
O	1491	1501	multifocal
O	1502	1507	group
O	1508	1516	compared
O	1517	1519	to
O	1520	1523	the
O	1524	1532	unifocal
O	1533	1538	group
O	1538	1539	,
O	1540	1547	further
O	1548	1553	nodal
O	1554	1565	involvement
O	1566	1571	after
O	1572	1573	a
O	1574	1582	positive
O	1583	1591	sentinel
O	1592	1596	node
O	1597	1600	was
O	1601	1608	similar
O	1609	1611	in
O	1612	1616	both
O	1617	1623	groups
O	1623	1624	.

O	1625	1629	This
O	1630	1638	suggests
O	1639	1643	that
O	1644	1647	the
O	1648	1651	SNB
O	1652	1661	procedure
O	1662	1664	is
O	1665	1669	safe
O	1670	1672	in
O	1673	1681	patients
O	1682	1686	with
O	1687	1697	multifocal
O	1698	1704	breast
O	1705	1711	cancer
O	1711	1712	.
